Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suprimun
- Development stage
- Phase 3
- Lead developer
- Amega Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Suprimun is an immunosuppressant small molecule developed and marketed by Amega Biotech. It is a prodrug of mycophenolic acid (MPA), which acts by inhibiting inosine monophosphate dehydrogenase (IMPDH). This inhibition leads to the depletion of guanine nucleotides, which are essential for DNA synthesis in T and B lymphocytes, thereby suppressing their proliferation. Suprimun is indicated for the prophylaxis of acute organ rejection in patients receiving allogeneic kidney, heart, or liver transplants, typically used in combination with cyclosporine and corticosteroids.
- Brand names
- Suprimun
- Other names
- mycophenolate mofetil
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on Suprimun.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suprimun.